Diabetes mellitus is a group of conditions in which blood glucose remains too high because the body makes too little insulin or cannot use it effectively. The main forms are type 1 diabetes, type 2 diabetes, and gestational diabetes, which develops d...
Search Bar & Filters
Found 493 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating erectile function changes in male patients who undergo percutaneous coronary intervention PCI for either a heart attack or stable angina. The study aims to understand how myocardial infarction affects erectile function over time and to explore whether erectile dysfunction can predict future cardiac events. This observational study compares erectile function between patients with myocardial infarction and those with stable angina using standardized questionnaires. Participants are grouped into two sets those treated with PCI after a heart attack and those treated due to stable angina. Erectile function is assessed at baseline after recovery from PCI, and at 3 and 6 months post-procedure using the International Index of Erectile Function IIEF questionnaire. Additional assessments include the Beck Depression Inventory and Fear of Cardiac Recurrence and Progression Scale. Researchers also collect clinical data such as cardiac vessel scores, ejection fraction, testosterone levels, body measurements, medication use, and the intervention method. During the study, male participants aged 30 to 75 will complete face-to-face interviews and questionnaires at specified intervals baseline, 3 months, and 6 months after PCI. The study measures changes in erectile function scores over time and examines associations with cardiac health, depression, and anxiety symptoms. Safety and participation are monitored throughout the follow-up period. The total duration of involvement is up to 6 months, with evaluations focusing on erectile function and related health parameters.
Actively Recruiting
Researchers are evaluating an AI-assisted digital health tool called the Smart family doctor to improve control of hypertension, diabetes, and dyslipidemia in adults who have undergone coronary artery bypass grafting CABG or percutaneous coronary intervention PCI. This study uses a randomized controlled design involving about 536 participants across 5-10 hospitals. Participants must be adults aged 18 or older with a history of CABG or PCI and the specified conditions. Participants in the experimental group will use the AI-assisted Smart family doctor app that provides personalized health education, targeted guidance on managing blood pressure, blood sugar, medication adherence, exercise, and smoking cessation. They will also receive tailored reminders and can report self-measured health data for feedback. Both groups receive weekly 3-hour health management guidance from health managers, and participants will wear a smart band daily for health data collection during the 6-month study period. Throughout the study, participants will be assessed for control rates of hypertension, diabetes, and hyperlipidemia at 6 months. Additional measures include blood pressure, cholesterol levels, blood glucose, physical activity, quality of life, psychological status, and cognitive function. The study monitors health data continuously via smart bands and collects self-reports and clinical assessments to evaluate the interventions impact over the 6 months.
Actively Recruiting
Healthy Volunteer
This research aims to explore how a dietary supplement called the Insulin Balance Formula may help support healthy insulin levels and its effects on weight, fatigue, and sugar cravings. The study focuses on generally healthy adults who want to maintain healthy insulin levels and improve overall metabolic health using this nutritional approach. It is an observational study where participants act as their own control in a single-arm design to detect initial signals of benefit and gather safety data. Participants will take the Insulin Balance Formula supplement daily for 30 days, starting with one capsule to assess tolerance and increasing to three capsules, ideally one before each meal or all at once. The formula contains five ingredients Berberine, Beta Alanine, Zinc Citrate, Folate, and Fenugreek Extract. During the study, participants will follow a balanced diet and avoid introducing new supplements or health interventions. Throughout the 30-day period, participants will complete several assessments, including body composition measurement, the PROMIS Sleep Disturbance Scale, the Carbohydrate Craving Questionnaire, and evaluations of hunger and fatigue after meals. These will be done at baseline and study completion, with some hunger and fatigue assessments repeated randomly during the study. Participants are encouraged to provide honest feedback, and their privacy is protected. The study aims to generate meaningful data on how this supplement may support metabolic health and guide future research.
Actively Recruiting
Healthy Volunteer
Researchers are conducting a Phase I clinical trial to compare the bioavailability and safety of different forms of SHR-3167 injection in healthy adults between 18 and 55 years old. This study aims to understand how the drug is absorbed and processed in the body, focusing on the maximum plasma concentration and overall exposure to the drug over time. Participants will receive one of three different specifications of SHR-3167 injection in a randomized, parallel, and open-label design. The study will monitor the drugs levels in the blood from Day 1 through Day 71, including measurements such as maximum concentration, area under the curve, time to reach maximum concentration, and half-life. Safety will be assessed by tracking any adverse events and immune responses during this period. During the study, participants will undergo physical exams, vital signs checks, ECGs, chest X-rays, and laboratory tests to ensure health status. Blood samples will be collected multiple times to analyze drug levels and antibodies. The study lasts about 71 days, with continuous monitoring for safety and drug behavior. Participants must comply with study procedures and provide informed consent before joining.
Actively Recruiting
Researchers are evaluating TQF3250 capsules, a biased GLP-1 receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., in healthy adult subjects with hyperglycemia. This Phase 1a clinical trial aims to study the safety, tolerability, and pharmacokinetic characteristics of TQF3250 after single administration and escalating doses. The capsule selectively activates certain pathways of the GLP-1 receptor to potentially offer better effects with fewer side effects. Participants will be randomly assigned to receive either a TQF3250 capsule or placebo. The treatment involves oral administration in two cycles of 10 days each. One group will take the capsule while fasting once, and the other group will take it once per cycle after eating to assess the foods influence. The study uses quadruple masking to maintain blinding. During the study, participants will be monitored closely for adverse events, vital signs, electrocardiograms, and laboratory test results up to 20 days. Researchers will assess changes in body temperature, heart rate, respiratory rate, blood pressure, and blood oxygen levels within 24 hours of dosing. Pharmacokinetic measures such as peak drug concentration and drug exposure over time will also be evaluated. Participants are expected to comply with study procedures and dietary requirements throughout the trial.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate a culturally relevant micronutrient-dense plant-rich mNDPR dietary intervention designed to reduce obesity and related disease risks among Native American employees of Twin Arrows Casino. Native Americans face higher rates of obesity and Type II diabetes compared to non-Hispanic Whites. The study involves a randomized controlled trial to assess improvements in physical health measures, wellness, and healthcare costs over one year. Participants will be randomly assigned to either an experimental group receiving a 12-week mNDPR nutrition program or a wait-list control group. The intervention includes a 2-hour initial group session followed by weekly 1-hour coaching sessions led by trained Native American Masters of Public Health students using Motivational Interviewing. Sessions provide nutrition education, cooking demonstrations, workplace dining tours, and social support. The wait-list control group will maintain usual eating habits during the first 12 weeks before receiving the same intervention. Participants will undergo health and wellness assessments at baseline and after 13 weeks, with additional diet recall at week 26 for the experimental group and follow-up measures for the control group. Healthcare utilization will be reviewed at 52 weeks. Researchers will measure changes in Hemoglobin A1c, fasting glucose, insulin, blood lipids, inflammatory markers, blood pressure, and wellness indicators like anxiety and sleep quality. Adherence to the diet will be monitored weekly, alongside attendance and self-monitoring of diet compliance.
Actively Recruiting
Healthy Volunteer
This research aims to explore how PhytoRx Families, an innovative produce prescription program, can impact nutrition, health, and healthcare use among families in rural North Carolina facing food insecurity. The study focuses on adults and school-aged children, addressing barriers like limited access to affordable healthy food in lower-resourced rural communities. Participants include 30 adult-child pairs with children aged 8 to 14 years. Healthcare providers at local clinics will refer eligible families who screen positive for food insecurity. The program provides fresh produce boxes and nutrition education over a 16-week period, aiming to improve fruit and vegetable intake and related health outcomes. During the study, participants will complete dietary recalls and health assessments at the start and end of the 16 weeks. Researchers will measure fruit and vegetable intake, diet quality, food security, blood pressure, HbA1C, body mass index, and various nutrition-related behaviors. The study will also track healthcare usage and evaluate changes over the intervention period.
Actively Recruiting
Researchers are evaluating a fruit and vegetable prescription F&V Rx program designed to improve diabetes management among low-income Hispanic adults with type 2 diabetes. The study aims to test how F&V prescriptions affect participation in diabetes self-management education and support DSMES, fruit and vegetable intake, diet quality, blood sugar control measured by hemoglobin A1c, and the programs acceptability and sustainability. This pilot randomized controlled trial addresses gaps in understanding the role of F&V prescriptions combined with DSMES attendance in diabetes care. The study includes three groups one receiving usual care, one receiving usual care plus four monthly F&V Rx vouchers regardless of DSMES attendance, and one receiving usual care plus F&V Rx vouchers contingent on monthly DSMES group attendance over 16 weeks. Participants in the intervention groups receive vouchers to purchase fruits and vegetables at local stores. The trial tests the impact of these approaches on education uptake and retention as well as health and dietary outcomes. Participants will attend study visits at the beginning and end of the 16-week period for assessments including blood samples for A1c and plasma carotenoids, dietary intake surveys, and diabetes self-management questionnaires. Researchers will monitor voucher use, DSMES attendance, and collect feedback from both participants and care providers to evaluate program implementation. The study is conducted with cultural adaptations and community involvement to support relevance for Hispanic adults with type 2 diabetes.
Actively Recruiting
Researchers are evaluating a new digital tool called Prioritize Personalize Prescribe Exercise P3-EX designed to help clinicians prescribe customized exercise plans to patients with cardiovascular disease CVD risk factors such as obesity, hypertension, dyslipidemia, and diabetes. This pilot randomized controlled crossover trial aims to test the usability and satisfaction of P3-EX compared to a standard exercise prescription method called the American College of Sports Medicine Physical Activity Vital Sign ACSM-PAVS. Clinicians including physicians, physician assistants, and advanced practice registered nurses will recruit patients with CVD risk factors and deliver exercise prescriptions using either P3-EX or ACSM-PAVS in a random sequence crossover design. Patients will follow their assigned exercise program for 12 weeks with virtual weekly oversight from University of Connecticut Graduate Research Assistants. Each patient will receive an exercise information packet, virtual guidance visits, and weekly progressive exercise goals by email. Clinicians and patients will complete usability and satisfaction questionnaires within 48 hours after each exercise prescription delivery. Participants will attend in-person visits at the start and end of the study to assess cardiovascular health, physical activity levels using accelerometers, and exercise adherence recorded in self-report diaries. Blood tests for lipid and glucose profiles will be performed at local labs. The study measures feasibility and acceptability of P3-EX as the primary outcome, and explores changes in patient cardiovascular risk factors, physical activity, and exercise adherence as secondary outcomes. The total participation involves baseline assessments, 12 weeks of exercise intervention, and post-intervention evaluations.
Actively Recruiting
Healthy Volunteer
This research aims to explore the link between new-onset or worsening diabetes and the later development of pancreatic cancer. It focuses on individuals over 50 years old who have either been diagnosed with diabetes within the past year or have experienced deteriorating diabetes recently. The study uses Magnetic Resonance Imaging and Magnetic Cholangiopancreatography MRIMRCP to screen for early pancreatic cancer or its precursors, helping to identify risks earlier. Participants will undergo an MRI with contrast at the start of the study. Any abnormalities found will be reviewed by a team of specialists and discussed with the participant. Blood samples will be collected every six months for up to three years to create a bio-bank that supports developing a blood test for pancreatic cancer. Additional MRI scans may be done as needed based on expert recommendations. During the study, participants will complete a brief psychological survey and provide blood samples regularly. Researchers will monitor the presence of early pancreatic cancer or precursor lesions over three years. The study tracks the relative risk of pancreatic cancer among those with new or worsening diabetes. Participants must be willing to undergo MRI screening, provide informed consent, and attend all study visits during this period.
1-10 of 493
1